Search results for "Biological Product"

showing 10 items of 126 documents

Morphogenetic (Mucin Expression) as Well as Potential Anti-Corona Viral Activity of the Marine Secondary Metabolite Polyphosphate on A549 Cells

2020

The mucus layer of the nasopharynx and bronchial epithelium has a barrier function against inhaled pathogens such as the coronavirus SARS-CoV-2. We recently found that inorganic polyphosphate (polyP), a physiological, metabolic energy (ATP)-providing polymer released from blood platelets, blocks the binding of the receptor binding domain (RBD) to the cellular ACE2 receptor in vitro. PolyP is a marine natural product and is abundantly present in marine bacteria. Now, we have approached the in vivo situation by studying the effect of polyP on the human alveolar basal epithelial A549 cells in a mucus-like mucin environment. These cells express mucins as well as the ectoenzymes alkaline phospha…

Aquatic OrganismsSecondary MetabolismVirus AttachmentPharmaceutical ScienceAdenylate kinaseRespiratory MucosaMucin 5ACdigestive systemArticle03 medical and health sciences0302 clinical medicinemucinPolyphosphatesDrug Discoveryotorhinolaryngologic diseasesExtracellularHumansReceptorlcsh:QH301-705.5neoplasmsinnate immunityPharmacology Toxicology and Pharmaceutics (miscellaneous)MUC1030304 developmental biologyA549 cellBiological Products0303 health sciencesBacteriaSARS-CoV-2ChemistryCell growthMucin-1MucinCOVID-19polyphosphaterespiratory systemImmunity Innatedigestive system diseasesSARS-CoV-2 spike proteinADKCell biologyATPlcsh:Biology (General)A549 Cells030220 oncology & carcinogenesishydrogelhuman alveolar cellsMarine Drugs
researchProduct

A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study

2022

Abstract Background Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133/100,000, while in the Italian population is 90–420/100,000. Traditionally, nonsteroidal anti-inflammatory drugs, glucocorticoid, and disease-modifying antirheumatic drugs have been used in the treatment of PsA. However, for those patients who are not adequately controlled with conventional therapies, the new biologics compounds represent a valid option. Biologic therapies have been shown to be more effective but also more expensive than conventional systemic …

Biological ProductsBiologicCostHealth PolicyArthritis PsoriaticPsoriatic arthritiTumor necrosis factor.Cost-per-responderBiological TherapyTreatment OutcomeReal-worldAntirheumatic AgentsHumansLongitudinal StudiesSecukinumabBMC Health Services Research
researchProduct

Editorial: Chemoprevention of cancer by natural products

2019

Biological ProductsCancer ResearchMedical educationbusiness.industryDrug discoveryMEDLINECancermedicine.diseaseChemopreventionNatural (archaeology)Drug DevelopmentOncologyDrug developmentNeoplasmsDrug DiscoveryHumansMedicinebusinessIntroductory Journal ArticleCancer Letters
researchProduct

Natural products for the treatment of Type 2 Diabetes Mellitus

2015

Type 2 diabetes mellitus is a metabolic disease characterized by persistent hyperglycemia. High blood sugar can produce long-term complications such as cardiovascular and renal disorders, retinopathy, and poor blood flow. Its development can be prevented or delayed in people with impaired glucose tolerance by implementing lifestyle changes or the use of therapeutic agents. Some of these drugs have been obtained from plants or have a microbial origin, such as galegine isolated from Galega officinalis, which has a great similarity to the antidiabetic drug metformin. Picnogenol, acarbose, miglitol, and voglibose are other antidiabetic products of natural origin. This review compiles the princi…

Blood GlucosePeroxisome Proliferator-Activated ReceptorsPharmaceutical ScienceMedical PlantsPharmacologyAnalytical ChemistryDrug DiscoveryGlucose homeostasisAcarboseClinical Trials as Topicdiabetesbiologyfood and beverages//purl.org/becyt/ford/3.1 [https]Medicina BásicaMolecular Medicine//purl.org/becyt/ford/3 [https]medicine.drugFarmacología y Farmaciamedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDBlood sugarfoodInternal medicineYerba-mateVoglibosemedicineDiabetes MellitusHumansHypoglycemic AgentsGlycoside Hydrolase InhibitorsClinical TrialsPharmacologyBiological Productsclinical trialsPlants Medicinalantidiabeticbusiness.industryMiglitolOrganic ChemistryType 2 Diabetes Mellitusalpha-Glucosidasesbiology.organism_classificationfood.foodEndocrinologyDiabetes Mellitus Type 2Complementary and alternative medicineAntidiabeticHyperglycemiaCiencias MédicasGalega officinalisalpha-Amylasesbusinessmedicinal plants
researchProduct

Medical management of Crohn's disease

2011

The medical approach to Crohn's disease has been modified in recent years thanks to the introduction of new therapies, like biologics. Also, well-designed studies and systematic reviews have allowed better evaluation of the role of old drugs like steroids and immunosuppressors. This review aims to evaluate the recent evidence on the medical approach to Crohn's disease in the different settings of the disease.Randomized controlled trials and meta-analyses were included in the review. The research on all the studies discussed was based on the Cochrane Library, Medline and Embase, using the following medical subject headings: Crohn's disease, clinical trial, therapy, 5-aminosalicylic acid, ste…

Budesonidemedicine.medical_specialtyPathologyAnti-Inflammatory AgentsMEDLINEDiseaseCochrane LibraryManagement of Crohn's diseaselaw.inventionCrohn DiseaseRandomized controlled trialAdrenal Cortex HormoneslawmedicineHumansPharmacology (medical)BudesonideIntensive care medicineBone Marrow TransplantationPharmacologyBiological ProductsTumor Necrosis Factor-alphabusiness.industryRemission InductionGeneral Medicinemedicine.diseaseAnti-Bacterial AgentsIntestinesClinical trialAminosalicylic AcidsMethotrexateTreatment OutcomeSystematic reviewPurinesbusinessImmunosuppressive Agentsmedicine.drugExpert Opinion on Pharmacotherapy
researchProduct

Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pande…

2020

Background Starting December 2019, mankind faced an unprecedented enemy, the COVID-19 virus. The world convened in international efforts, experiences and technologies in order to fight the emerging pandemic. Isolation, hygiene measure, diagnosis, and treatment are the most efficient ways of prevention and intervention nowadays. The health organizations and global care systems screened the available resources and offered recommendations of approved and proposed medications. However, the search for a specific selective therapy or vaccine against COVID-19 remains a challenge. Methods A literature search was performed for the screening of natural and derived bio-active compounds which showed po…

COVID-19 VaccinesSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Drug Evaluation PreclinicalPharmaceutical ScienceAntiviral AgentsArticle03 medical and health scienceschemistry.chemical_compoundClinical trials0302 clinical medicineTocilizumabChloroquineDrug DiscoveryPandemicmedicineHumansAntiviralPandemics030304 developmental biologyPharmacologyBiological ProductsClinical Trials as TopicNatural products0303 health sciencesProtectionMolecular StructureTraditional medicineSARS-CoV-2business.industryCOVID-19LycorineFingolimodCOVID-19 Drug TreatmentClinical trialConessineComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicinePatentPlant Preparationsbusinessmedicine.drugPhytomedicine
researchProduct

Natural products as inhibitors of recombinant cathepsin L of Leishmania mexicana.

2015

Cysteine proteinases (cathepsins) from Leishmania spp. are promising molecular targets against leishmaniasis. Leishmania mexicana cathepsin L is essential in the parasite life cycle and a pivotal in virulence factor in mammals. Natural products that have been shown to display antileishmanial activity were screened as part of our ongoing efforts to design inhibitors against the L. mexicana cathepsin L-like rCPB2.8. Among them, agathisflavone (1), tetrahydrorobustaflavone (2), 3-oxo-urs-12-en-28-oic acid (3), and quercetin (4) showed significant inhibitory activity on rCPB2.8 with IC50 values ranging from 0.43 to 18.03 µM. The mechanisms of inhibition for compounds 1–3, which showed Ki values…

Cathepsin LImmunologyLeishmania mexicanaVirulence factorLeishmania mexicanaCathepsin BCathepsin LInhibitory Concentration 50Non-competitive inhibitionparasitic diseasesmedicineBiflavonoidsHumansCathepsinBiological ProductsbiologyGeneral Medicinebiology.organism_classificationLeishmaniaRecombinant ProteinsKineticsInfectious DiseasesMechanism of actionBiochemistrybiology.proteinParasitologyQuercetinmedicine.symptomUncompetitive inhibitorExperimental parasitology
researchProduct

Targeting multiple myeloma with natural polyphenols

2019

Multiple myeloma (MM) is still an incurable hematologic malignancy. Although new therapeutic strategies have been developed to target different pathways in malignant cells, such as proliferation, differentiation, and apoptosis, better survival rates have also been achieved by the introduction of autologous stem cell transplantation (ASCT). Hematopoietic stem cell transplantation and novel targeted agents, such as proteasome inhibitors, monoclonal antibodies, immunomodulatory drugs, check-point inhibitors and epigenetic modulators, have significantly achieved long remission time and increased survival rates. However, most patients relapse, develop resistance, and eventually die because of re…

Cell Survivalmedicine.drug_classmedicine.medical_treatmentHematopoietic stem cell transplantationMonoclonal antibody01 natural sciencesNatural polyphenols Multiple myeloma Anticancer drug03 medical and health sciencesAutologous stem-cell transplantationDrug DiscoverymedicineAnimalsHumansEpigeneticsMultiple myelomaCell Proliferation030304 developmental biologyPharmacologyBiological Products0303 health sciences010405 organic chemistryDrug discoveryChemistryOrganic ChemistryTherapeutic effectPolyphenolsfood and beveragesCancerGeneral Medicinemedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaAntineoplastic Agents Phytogenic0104 chemical sciencesSettore BIO/14 - FarmacologiaCancer researchMultiple MyelomaEuropean Journal of Medicinal Chemistry
researchProduct

In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopha…

2018

The ability to predict new chemical entity performance using in vivo animal models has been under investigation for more than two decades. Pharmaceutical companies use their own strategies to make decisions on the most appropriate formulation starting early in development. In this paper the biopharmaceutical decision trees available in four EFPIA partners (Bayer, Boehringer Ingelheim, Bristol Meyers Squibb and Janssen) were discussed by 7 companies of which 4 had no decision tree currently defined. The strengths, weaknesses and opportunities for improvement are discussed for each decision tree. Both pharmacokineticists and preformulation scientists at the drug discovery & development interf…

Chemistry PharmaceuticalDecision treePharmaceutical ScienceBiological Availability02 engineering and technology030226 pharmacology & pharmacyBiopharmaceutics03 medical and health sciences0302 clinical medicineDrug DevelopmentIn vivoNew chemical entityDrug DiscoveryAnimalsHumansBiological ProductsManagement scienceDrug discoveryDecision TreesGeneral Medicine021001 nanoscience & nanotechnologyClinical trialIdentification (information)BiopharmaceuticalDrug development0210 nano-technologyBiotechnologyEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Taxonomic Identity, Geographic Distribution, and Commercial Exploitation of the Culinary-Medicinal Mushroom Pleurotus nebrodensis (Basidiomycetes)

2016

An updated overview of the outcome of studies conducted on the culinary-medicinal mushroom Pleurotus nebrodensis is presented by placing emphasis on the clarification of the taxonomic identity of P. nebrodensis and other related taxa possessing entirely white to cream basidiomes, which grow in association with different plants of the family Apiaceae. Cultivation techniques, quality of the product sold and sales price, as well as nutritional and medicinal aspects are discussed. Taking also into consideration the high economic importance of P. nebrodensis, it is essential to proceed with the verification of the commercial strains currently available in the international market under the name …

ChinaIdentity (social science)010501 environmental sciencesBiologyPleurotusDNA Ribosomal01 natural sciencesApplied Microbiology and Biotechnologymedicinal and edible mushrooms fungal taxonomy medicinal use Umbellifers Pleurotus nebrodensisMedicinal mushroomSpecies Specificity0502 economics and businessDrug DiscoveryBotanyHumansDNA FungalPhylogeny0105 earth and related environmental sciencesPharmacologyPleurotus nebrodensisBiological ProductsMushroomGeographyGreeceSettore BIO/02 - Botanica Sistematica05 social sciencesFungal geneticsbiology.organism_classificationGeographic distributionTaxonItalyFoodSettore BIO/03 - Botanica Ambientale E ApplicataSale price050203 business & managementInternational Journal of Medicinal Mushrooms
researchProduct